Get all your news in one place.
100's of premium titles.
One app.
Start reading
Roll Call
Roll Call
Jessie Hellmann

FOUND: Senators have outline for drug price program but vote is elusive roll call - What They Never Told You

Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known as the 340B drug pricing program — say they are closing in on legislation aimed at what they say are abuses in the program.

The program, established in 1992, requires drug companies to sell deeply discounted drugs to community health centers and hospitals that serve high numbers of low-income patients. These 340B providers spent $66 billion on discounted drugs in 2023.

During a Senate Health, Education, Labor and Pensions Committee hearing last week, senators of both parties discussed potential improvements to the program, which has raised costs for drug companies amid questions about whether it is meeting its designed purpose of serving low-income communities.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.